Erythropoiesis-stimulating agents and thrombotic events in dialysis patients
Erythropoiesis-stimulating agents (ESA) have been associated with a higher cardiovascular event and mortality rate in dialysis patients. The ESA-associated risk of arterial thrombotic events is mainly based on composite endpoints of anemia-correction trials targeting high hemoglobin levels. The ESA-associated risk of venous thromboembolism (VTE) has not been studied in dialysis patients yet. We therefore aimed to determine the association between ESA use and dose with ischemic stroke, myocardial infarction (MI) and VTE.
Source: Thrombosis Research - Category: Hematology Authors: Marit M. Suttorp, Tiny Hoekstra, Gürbey Ocak, Anouk T.N. van Diepen, Ilka Ott, Moshe Mittelman, Ton J. Rabelink, Raymond T. Krediet, Friedo W. Dekker Tags: Regular Article Source Type: research
More News: Anemia | Cardiology | Cardiovascular | Dialysis | Heart | Heart Attack | Hematology | Ischemic Stroke | Stroke | Thrombosis